Actively Recruiting
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
Led by UNICANCER · Updated on 2024-10-18
14750
Participants Needed
1
Research Sites
1149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic cancer. Study of the original cohort will be focused on localized breast cancer patients, other localisation in non-metastatic setting will be explored furtherwise, fist of all in lung cancer. The project will include four specific aims : 1. To develop a database of chronic treatment related toxicity in a cohort of 14750 women with stage I-III breast cancer (= non metastatic), whatever these treatments are (surgery; radiation therapy; chemotherapy …) 2. To describe incidence, clinical presentation, and outcome of chronic toxicities. 3. To describe the psychological, the social and the economic impacts of chronic toxicities. 4. To generate predictors for chronic toxicities in order to prevent them, based upon biological criteria. The expected impact of these toxicities, when identified, will be to improve quality of life and to decrease health cost, by the early identification of patients at high risk of toxicity. Such early identification could lead to prevent toxic effect by: a. developing prevention strategies, b. substituting toxic treatment by a non (less) toxic one. Also, such cohort will offer a quantification of the impact of treatment toxicity, that could be further used to quantify medical usefulness of strategies that aim at decreasing treatment toxicities (implementation of predictive biomarker for resistance, cytotoxic-free regimen etc…)
CONDITIONS
Official Title
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women
- Aged 18 years and over
- Diagnosed with invasive breast cancer by cytology or histology
- No clinical evidence of metastasis at the time of inclusion
- Untreated for breast cancer including surgery not yet performed
- Receiving social security coverage
- Able to understand and communicate in French
- Provided free and informed consent for biological samples, questionnaires, and resource usage data
- Since February 2022, either under 45 years old at diagnosis, or have CT2-3, cN0-3, HER2+ (HR+ or HR-), or HR-HER2-
- Or eligible for Pembrolizumab, Olaparib, TDM1, Abemaciclib, or Ribociclib
You will not qualify if you...
- Metastatic breast cancer
- Local recurrence of breast cancer
- History of cancer within 5 years before study entry except basal cell skin cancer or carcinoma in situ of the cervix
- Already received treatment for breast cancer
- Blood transfusion within the last 6 months
- Persons deprived of liberty or under legal supervision (including guardianship)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Gustave roussy
Villejuif, France, 94805
Actively Recruiting
Research Team
C
Catherine Gaudin
CONTACT
A
Anne Laure Martin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here